Breaking News, Collaborations & Alliances

Astellas, ClearPath Form Strategic Vax Portfolio Pact

Launches RSV Corp. to develop virosome vaccine technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Astellas Pharma and ClearPath Development Co. have entered a strategic partnership to form a portfolio of development companies focused on vaccines for infectious diseases. The partnership will support Astellas’ global vaccine franchise with the launch of the first company, RSV Corp. (RSVC). Astellas will fund RSVC’s development of a virosome vaccine technology, licensed from Mymetics Corp., for respiratory syncytial virus (RSV), through Phase IIb proof-of-concept. Astellas will have...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters